Abstract
Valdecoxib is a non-steroidal anti-inflammatory drug used in the treatment of rheumatoid and osteoarthritis. It is practically insoluble in water. Incidence of adverse events such as nausea has been reported in some trials. Therefore, an attempt was made to improve the aqueous solubility of the drug by making an inclusion complex using hydroxypropyl βeta-cyclodextrin (HPβ-CD). The complexes were prepared by physical mixture and freeze-drying methods. The different methods employed for evaluation—including differential scanning calorimetry, Fourier transform infrared spectral analysis, and scanning electron microscopy studies—indicated complete formation of the complex by the freeze-drying method in a molar ratio of 1:1. The prepared complexes showed an improved in vitro dissolution profile and better anti-inflammatory activity as compared to the pure drug.
Footnotes
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.